Navigation Links
Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics
Date:12/18/2013

DUBLIN, Dec. 18, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/mqs7t3/merger_and) has announced the addition of the "Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

The Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the merger and acquisition agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter merger and acquisition deals.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all merger and acquisition deals announced since 2009 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual merger and acquisition contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Key Topics Covered:

Executive Summary

1. Introduction

2. Trends in M&A dealmaking
2.1. Introduction
2.2. Difference between merger and acquisition deals
2.3. Trends in M&A deals since 2009
2.4. When M&A can be useful
2.5. Attributes of M&A deals
2.6. Partnering deals with M&A component
2.7. Bigpharma mega mergers - are we at the end of the road?
2.8. Accessing innovation through M&A
2.9. The emerging role of private equity in M&A
2.10. Implementing M&A transactions
2.11. Joint ventures as alternative to M&A
2.12. The future of M&A in biopharma

3. Overview of M&A deal structure
3.1. Introduction
3.2. Pure versus multi-component acquisition deals
3.3. Pure M&A agreement structure
3.4. Acquisition as part of a wider alliance agreement
3.5. Merger agreements

4. Leading M&A deals
4.1. Introduction
4.2. Top M&A deals by value
4.3. Top merger deals
4.4. Bigpharma M&A deal activity

5. Bigpharma M&A deals
5.1. Introduction
5.2. How to use M&A deals
5.3. Bigpharma company M&A deal profiles

6. M&A contracts directory
6.1. Introduction
6.2. Company A-Z
6.3. By industry sector

Companies Mentioned:

  • Abbott Japan
  • Bristol-Myers Squibb
  • Cytokinetics
  • Dyax
  • Exelixis
  • GlaxoSmithKline
  • Hyperion Therapeutics
  • Ironwood Pharmaceuticals
  • Janssen Research & Development
  • KaloBios Pharmaceuticals
  • La Jolla Pharmaceutical
  • Millennium
  • Nycomed
  • Ortho Biotech
  • Procter & Gamble Pharmaceuticals
  • Seattle Genetics
  • Serono
  • Sigma-Tau
  • Solvay
  • Somaxon Pharmaceuticals
  • Spectrum Pharmaceuticals
  • Transcept Pharmaceuticals
  • Ucyclyd Pharma
  • Victory Pharma
  • Warner Chilcott
  • Watson Pharmaceuticals
  • Wyeth
  • Xenoport
  • Zogenix
  • ZymoGenetics

For more information visit http://www.researchandmarkets.com/research/mqs7t3/merger_and

Media Contact:

Laura Wood , +353-1-481-1716, press@researchandmarkets.net


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Spotlight Innovation, Inc. Announces Name Change and Closing of Merger
2. PharmAthene Announces Termination Of Merger Agreement With Theraclone Sciences
3. Steep Hill Laboratories and Halent Scientific Proudly Announce Historic Merger
4. 3SBio Inc. Announces Completion of Merger
5. 3SBio Inc. Enters Into Merger Agreement For "Going Private" Transaction
6. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
7. Epilepsy Foundation and Epilepsy Therapy Project Finalize Merger To Create Strong, Unified Organization To Support People with Epilepsy
8. Perrigo Company And Elan Corporation plc Receive Irish High Court Approval For Perrigos Proposed Acquisition Of Elan
9. Hart-Scott-Rodino Waiting Period Expires for Shires Acquisition of ViroPharma
10. Covington Advises Salix in $2.6 Billion Acquisition of Santarus
11. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Financial Highlights (in ... Months Ended December 31,Twelve Months Ended December 31,20162015% ... $           300$     ... Revenue 3539(10)%9498(4)%Kuvan Net Product Revenue ... 756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... - The Fight Against Cancer Innovation Trust (FACIT) and ... to report that Fusion Pharmaceuticals Inc. (Fusion) has closed ... Innovation – JJDC, Inc. (JJDC) as the lead investor. ... Partners, and Genesys Capital, as well as founding investor ... ...
(Date:2/23/2017)... 23, 2017  In Atlanta, it seems everyone has a ... intertwine to create an expressive and dynamic community unlike any ... and contribute to it. With their newest ... seeks to carry on that tradition with a unique, ... salon is the newest of 13 nationwide locations, ...
(Date:2/23/2017)... Minn. , Feb. 23, 2017  Imanis ... new product line of oncolytic vaccinia viruses for ... Corporation as part of Genelux,s proprietary, vaccinia virus-based ... are excited to enter into a partnership with ... selected oncolytic vaccinia viruses for use in research," ...
Breaking Biology Technology:
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute ... Larry Schlesinger as the Institute,s new President ... Biomed effective May 31, 2017. He is currently the Chair ... of the Center for Microbial Interface Biology at Ohio State ... as the new President and CEO of Texas Biomed," said ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to its ... meaningful advances worldwide, The Japan Prize Foundation today ... who have pushed the envelope in their respective ... Communication. Three scientists are being recognized with the ... that not only contribute to the advancement of ...
(Date:1/26/2017)... Jan. 26, 2017  Crossmatch, a leading provider of ... solution aimed at combatting fraud, waste and abuse in ... at the Action on Disaster Relief conference in ... for UN agencies and foreign assistance organizations throughout ... and abuse are a largely unacknowledged problem in the ...
Breaking Biology News(10 mins):